J Cancer 2024; 15(10):3095-3113. doi:10.7150/jca.94332 This issue Cite
Research Paper
1. Clinical Medical College, Southwest Medical University, Luzhou 646000, China.
2. Department of Oncology, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan 621000, China.
3. School of Science, Minzu University of China, Beijing 100081, China.
4. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, China.
5. Beijing University of Chinese Medicine, 100029, Beijing, China.
6. Department of Oncology, Beijing University of Chinese Medicine second affiliated Dong Fang hospital, 100078, Beijing, China.
7. Sichuan Provincial Center for Gynecology and Breast Diseases (Gynecology), Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
8. Department of Specialty Medicine, Ohio University, Athens 45701, OH, United States.
† These authors have contributed equally to this work.
Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is a common gynecologic tumor and patients with advanced and recurrent disease usually have a poor clinical outcome. Angiogenesis is involved in the biological processes of tumors and can promote tumor growth and invasion. In this paper, we created a signature for predicting prognosis based on angiogenesis-related lncRNAs (ARLs). This provides a prospective direction for enhancing the efficacy of immunotherapy in CESC patients. We screened seven OS-related ARLs by univariate and multivariate regression analyses and Lasso analysis and developed a prognostic signature at the same time. Then, we performed an internal validation in the TCGA-CESC cohort to increase the precision of the study. In addition, we performed a series of analyses based on ARLs, including immune cell infiltration, immune function, immune checkpoint, tumor mutation load, and drug sensitivity analysis. Our created signature based on ARLs can effectively predict the prognosis of CESC patients. To strengthen the prediction accuracy of the signature, we built a nomogram by combining signature and clinical features.
Keywords: CESC, LncRNAs, Angiogenesis, Immunotherapy, Chemotherapy, Prognostic signature